Hypertension Management in Black Female Patients

Initial Treatment

The American College of Cardiology recommends initiating treatment with a thiazide-type diuretic, such as chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 25-50 mg daily, as first-line monotherapy to address both elevated blood pressure and peripheral edema in black female patients 1, 2
Thiazide-type diuretics are more effective than RAS inhibitors or beta-blockers in lowering blood pressure in black patients and demonstrate superior cardiovascular event reduction compared to RAS inhibitors or alpha-blockers in this population 1, 2
Chlorthalidone is preferred over hydrochlorothiazide due to more robust cardiovascular disease risk reduction data and a longer therapeutic half-life 1, 2

A calcium channel blocker (CCB) such as amlodipine is equally acceptable as initial therapy in black patients, as CCBs are as effective as thiazide diuretics in lowering blood pressure and reducing cardiovascular events in this population 1, 3, 2
However, a CCB alone will not address the edema and may paradoxically worsen peripheral edema as a side effect, making it less ideal when edema is already present 1

If blood pressure remains >15/10 mmHg above goal after initiating monotherapy, immediately escalate to combination therapy rather than waiting 4, 2
The optimal two-drug combination for black patients is a CCB plus a thiazide diuretic, which provides additive blood pressure lowering and addresses the edema 1, 3, 4
An alternative effective combination is a CCB plus an ARB, as ACE inhibitors demonstrate reduced blood pressure lowering efficacy and increased risk of angioedema in black patients 1, 3, 4

Avoid ACE inhibitors as monotherapy in black patients due to reduced blood pressure lowering efficacy and increased risk of angioedema 1, 2
Most black patients with hypertension will require two or more medications to achieve blood pressure control below 130/80 mmHg, so anticipate the need for combination therapy 1, 2

Aim for blood pressure <130/80 mmHg in most patients, with individualization for elderly or frail patients based on tolerability 4, 2
Achieve target within 3 months of initiating therapy, with reassessment and medication adjustment if not at goal 4